You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微泰醫療-B(02235.HK)全球發售6352.95萬股 發售價每股30.5港元
格隆匯 10-18 06:28

格隆匯10月18日丨微泰醫療-B(02235.HK)發佈公吿,公司全球發售6352.95萬股股份,其中香港發售股份635.3萬股,國際發售股份5717.65萬股,另有15%超額配股權;發售價已釐定為每股發售股份30.50港元,每手買賣單位100股;高盛及中金公司為聯席保薦人;預期股份將於2021年10月19日於聯交所主板掛牌上市。

香港發售股份已獲小幅超額認購。合共接獲14,360份有效申請,認購合共4311.66萬股香港發售股份,相當於根據香港公開發售初步可供認購的H股總數約6.79倍。根據國際發售項下初步提呈發售的發售股份已獲小幅超額認購,相當於根據國際發售初步可供認購的國際發售股份總數的約4.9倍。基於發售價每股發售股份30.50港元,根據相關基石投資協議,公司的基石投資者已認購合共3917.13萬股H股。

按發售價每股發售股份30.50港元計算,公司將自全球發售收取的所得款項淨額估計約為18.151億港元(假設超額配售權未獲行使)。公司擬將所得款項淨額31%分配予核心產品;35%將分配予持續血糖監測系統;11%將分配至第二代貼敷式胰島素泵系統的臨牀前研究、臨牀試驗、註冊、生產及商業化;8%將分配至其他產品及在研產品的臨牀前研究、臨牀試驗、註冊、生產及商業化;5%將用於為建立基於雲端大數據的糖尿病管理平台提供資金;及10%將分配用於營運資金及其他一般公司用途。倘超額配售權獲悉數行使,則公司將就因超額配售權獲行使而將予發行及配發的952.94萬股額外發售股份收取額外所得款項淨額約2.781億港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account